Immune protection against anogenital HPV in Rwandan women with and without HIV following the introduction of quadrivalent HPV vaccination

INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have demonstrated population effectiveness in preventing cervical cancer. Evidence for protection of women with HIV (WWH) is lacking. In 2011, Rwanda introduced quadrivalent HPV vaccination nationally, primarily targeting girls in grade 6, providing an opportunity to evaluate its long-term effectiveness in WWH compared to women without HIV (WWoH). METHODS: Data from 3,058 of 3,148 (97.1%) Rwandan women with complete results from four sub-cohorts recruited and enrolled were analyzed: 769 WWoH born before 1996, 755 WWoH born 1996 or more recently, 773 WWH born before 1996, and 761 WWH born 1996 or more recently. We tested vaginal and anal specimens for high-risk HPV genotypes. We used self-report of HPV vaccination and measured anti-HPV16 antibodies levels by HPV16 VLP ELISA as HPV vaccination proxies to examine the protective effects, using logistic regression, of HPV vaccination on vaginal and/or anal (combined, "anogenital") HPV16 and/or HPV18 (HPV16/18). RESULTS: Self-reported HPV vaccination (vs. not) (adjusted odds ratio (aOR)=2.71, 95%CI=2.29-3.21) was most strongly positively, and WWH (vs. WWoH) (aOR=0.68, 95%CI=0.60-0.78) was most strongly negatively, associated with higher anti-HPV16 antibody levels. Anogenital HPV16/18 prevalence decreased from 11.0% to 2.5% in those with the lowest to highest quartile of anti-HPV16 antibody levels, respectively (ptrend<0.001). The highest quartile of anti-HPV16 antibody levels was associated with lower anogenital HPV16/18 (aOR=0.23, 95%CI=0.13-0.38); similar associations were observed for the highest quartile in WWH (aOR=0.23; 95%CI=0.12-0.46) as in WWoH (aOR=0.24, 95%CI=0.10-0.58). CONCLUSION: WWH who were likely vaccinated against HPV vaccination had lower prevalence of anogenital HPV16/18.

Authors

Institutions

Publication Details

Journal
JNCI Journal of the National Cancer Institute
Published
2026-11-17
DOI
https://doi.org/10.1093/jnci/djag430
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune protection against anogenital HPV in Rwandan women with and without HIV following the introduction of quadrivalent HPV vaccination

Yuanji Pan, Gallican Kubwimana, Léon Mutesa, Maria Demarco et al.
JNCI Journal of the National Cancer Institute
Cervical Cancer and HPV Research
article

Immune protection against anogenital HPV in Rwandan women with and without HIV following the introduction of quadrivalent HPV vaccination

Yuanji Pan, Gallican Kubwimana, Léon Mutesa, Maria Demarco, Philip E. Castle, Lígia A. Pinto, Troy J. Kemp, Marcel Yotebieng, Kathryn Anastos, Gad Murenzi, Faustin Kanyabwisha, Jean Paul Mivumbi, Obed Tuyishime, Julienne Nyirarukundo, Johanna Daily, Marie Gertrude Rutwaza
article en

Abstract

INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have demonstrated population effectiveness in preventing cervical cancer. Evidence for protection of women with HIV (WWH) is lacking. In 2011, Rwanda introduced quadrivalent HPV vaccination nationally, primarily targeting girls in grade 6, providing an opportunity to evaluate its long-term effectiveness in WWH compared to women without HIV (WWoH). METHODS: Data from 3,058 of 3,148 (97.1%) Rwandan women with complete results from four sub-cohorts recruited and enrolled were analyzed: 769 WWoH born before 1996, 755 WWoH born 1996 or more recently, 773 WWH born before 1996, and 761 WWH born 1996 or more recently. We tested vaginal and anal specimens for high-risk HPV genotypes. We used self-report of HPV vaccination and measured anti-HPV16 antibodies levels by HPV16 VLP ELISA as HPV vaccination proxies to examine the protective effects, using logistic regression, of HPV vaccination on vaginal and/or anal (combined, "anogenital") HPV16 and/or HPV18 (HPV16/18). RESULTS: Self-reported HPV vaccination (vs. not) (adjusted odds ratio (aOR)=2.71, 95%CI=2.29-3.21) was most strongly positively, and WWH (vs. WWoH) (aOR=0.68, 95%CI=0.60-0.78) was most strongly negatively, associated with higher anti-HPV16 antibody levels. Anogenital HPV16/18 prevalence decreased from 11.0% to 2.5% in those with the lowest to highest quartile of anti-HPV16 antibody levels, respectively (ptrend<0.001). The highest quartile of anti-HPV16 antibody levels was associated with lower anogenital HPV16/18 (aOR=0.23, 95%CI=0.13-0.38); similar associations were observed for the highest quartile in WWH (aOR=0.23; 95%CI=0.12-0.46) as in WWoH (aOR=0.24, 95%CI=0.10-0.58). CONCLUSION: WWH who were likely vaccinated against HPV vaccination had lower prevalence of anogenital HPV16/18.

JNCI Journal of the National Cancer Institute
Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Frederick National Laboratory for Cancer Research (US), Rwanda Military Hospital (RW), National Cancer Institute (US), Rwanda Biomedical Center (RW), Research for Development (RD Rwanda) (RW)
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon